VASRD 7914 · Endocrine System
Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) VA Disability Rating
DC 7914 covers a malignant — cancerous — neoplasm in any specified part of the endocrine system, thyroid cancer included. It carries one evaluation, 100 percent, and no lower tier of its own. That 100 percent continues through treatment and beyond it; six months after treatment is discontinued, a mandatory VA examination determines the rating that follows, and where there has been no local recurrence or metastasis the evaluation is then based on the residuals.
VA Rating Tiers
| Rating | Criteria |
|---|---|
| 100% | A malignant tumor of any endocrine gland. The 100 percent runs through treatment and for six months after it stops; a mandatory VA examination then decides what comes next, and if there is no recurrence or spread the rating moves to whatever residuals remain. |
How the VA Evaluates Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)
DC 7914 states a single criterion — "Neoplasm, malignant, any specified part of the endocrine system" — evaluated at 100 percent. Its Note controls everything after that: "A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals." Two things follow from that. The 100 percent evaluation is not graded by symptom severity — it attaches to the malignancy and to the treatment period, and the six months runs from the date treatment was discontinued. And there is no lower percentage under DC 7914 itself: once the mandatory examination has been done and there is no local recurrence or metastasis, the evaluation comes from the residuals, each rated under whichever diagnostic code fits it. A change of evaluation based on that examination or any later one is subject to § 3.105(e).
Veterans service-connected
~2,700 veterans
Vetrify editorial estimates informed by VA published claims data (VBA Annual Benefits Report) and the VA rating schedule — not official VA statistics.
Email me this Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) guide
Get the Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) rating criteria, evidence checklist, and strategy tips delivered to your inbox so you can review them anytime.
Best Evidence to Gather
- •The pathology report establishing the malignancy and the part of the endocrine system involved.
- •Oncology and surgical records showing each therapeutic procedure and the date the last one was discontinued, which is when the Note's six-month period begins.
- •Post-treatment imaging and follow-up notes addressing local recurrence and metastasis, the finding the Note makes decisive at the mandatory examination.
- •Documentation of the residuals of treatment, since these carry the evaluation once the 100 percent period ends.
Strategy Tips
- •Pin down the date the last therapeutic procedure was discontinued. The Note runs its six-month period from that date, and that is what fixes when the mandatory VA examination is due.
- •Keep the complete treatment record — surgery, X-ray therapy, antineoplastic chemotherapy, or other therapeutic procedures — since the Note ties the duration of the 100 percent evaluation to those procedures and their cessation.
- •Have the residuals documented before the mandatory examination rather than after it. Where there is no local recurrence or metastasis, the Note directs the rating to the residuals, and each is evaluated under the diagnostic code that covers it.
- •A change of evaluation following that examination, or any subsequent one, is subject to § 3.105(e) — the procedure the Note itself names.
C&P Exam Pitfalls
- •A mandatory examination that goes forward with no record of what the residuals actually are, leaving the evaluation that follows the 100 percent period resting on very little.
- •Treatment records that never state the date therapy was discontinued, which is the date the Note's six-month period runs from.
- •An examination that addresses only the affected gland and not the other residuals of surgery, radiation, or chemotherapy, which the Note directs the rating to.
Common Filing Mistakes
- •Filing the diagnosis without the treatment record. The Note ties the duration of the 100 percent evaluation to the therapeutic procedures and their cessation.
- •Treating the end of the 100 percent period as the end of the claim. Under the Note the evaluation continues on residuals, each under the diagnostic code that covers it.
- •No follow-up imaging or oncology note addressing recurrence or metastasis, which the Note makes the pivot at the mandatory examination.
- •Filing a thyroid-function claim here. An overactive thyroid is DC 7900, "Hyperthyroidism, including, but not limited to, Graves' disease"; DC 7914 is the malignant-neoplasm code.
Onset Patterns
- •DC 7914's timeline is set by treatment rather than by symptoms: the 100 percent evaluation continues beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure, and the six-month period before the mandatory VA examination starts when that treatment is discontinued.
- •After that examination, and absent local recurrence or metastasis, what remains to be evaluated is the residuals — which is why records of what the treatment left behind matter from the start.
Common questions about Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)
- Is Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) a VA-rated disability?
- Yes. The VA rates Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) under VASRD diagnostic code 7914 (Endocrine System). DC 7914 covers a malignant — cancerous — neoplasm in any specified part of the endocrine system, thyroid cancer included. It carries one evaluation, 100 percent, and no lower ti…
- What VA disability rating can I get for Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)?
- Possible VA ratings for Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) are 100%. Examples: 100%: A malignant tumor of any endocrine gland. The 100 percent runs through treatment and for six months after it stops; a mandatory VA examination then decides what comes next, and if there is no recurr…
- What evidence helps prove Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) for VA disability?
- Strong evidence for a Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) claim includes: The pathology report establishing the malignancy and the part of the endocrine system involved.; Oncology and surgical records showing each therapeutic procedure and the date the last one was discontinued, whic…
- What mistakes should veterans avoid when claiming Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)?
- Common pitfalls when filing for Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer): Filing the diagnosis without the treatment record. The Note ties the duration of the 100 percent evaluation to the therapeutic procedures and their cessation.; Treating the end of the 100 percent period as the end o…
Official sources
- 38 CFR § 4.119 — Schedule of ratings — endocrine system (Diagnostic Code 7914)
Rating criteria on this page are an educational summary of the cited regulation — the eCFR text is authoritative. See how Vetrify derives its numbers.
Estimate your combined rating
See how Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) combines with your other service-connected conditions using the official VA combined-ratings formula.
Open the calculator
VA Calc: Disability Pay
Combine your ratings & see monthly pay on your iPhone · Works offline